The estimated Net Worth of & Co., Inc.Merck Sharp & Do... is at least $23 Mille dollars as of 11 March 2024. Do owns over 21,397,205 units of Harpoon Therapeutics stock worth over $23,010 and over the last few years sold HARP stock worth over $0.
has made over 1 trades of the Harpoon Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently bought 21,397,205 units of HARP stock worth $492,135,715 on 11 March 2024.
The largest trade 's ever made was buying 21,397,205 units of Harpoon Therapeutics stock on 11 March 2024 worth over $492,135,715. On average, trades about 21,397,205 units every 0 days since 2024. As of 11 March 2024 still owns at least 1,000 units of Harpoon Therapeutics stock.
You can see the complete history of Do stock trades at the bottom of the page.
's mailing address filed with the SEC is 126 EAST LINCOLN AVENUE126 EAST LINCOLN AVENUE, , RAHWAYRAHWAY, NJNJ, 0706507065.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt e Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: